JP6684263B2 - 子癇前症の早期検出 - Google Patents
子癇前症の早期検出 Download PDFInfo
- Publication number
- JP6684263B2 JP6684263B2 JP2017500456A JP2017500456A JP6684263B2 JP 6684263 B2 JP6684263 B2 JP 6684263B2 JP 2017500456 A JP2017500456 A JP 2017500456A JP 2017500456 A JP2017500456 A JP 2017500456A JP 6684263 B2 JP6684263 B2 JP 6684263B2
- Authority
- JP
- Japan
- Prior art keywords
- anxa2
- subject
- level
- preeclampsia
- hescs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 201000011461 pre-eclampsia Diseases 0.000 title claims description 185
- 238000001514 detection method Methods 0.000 title description 4
- 102000004149 Annexin A2 Human genes 0.000 claims description 338
- 108090000668 Annexin A2 Proteins 0.000 claims description 338
- 238000000034 method Methods 0.000 claims description 82
- 239000000523 sample Substances 0.000 claims description 66
- 230000002357 endometrial effect Effects 0.000 claims description 65
- 229920002683 Glycosaminoglycan Polymers 0.000 claims description 53
- 238000002965 ELISA Methods 0.000 claims description 50
- 238000011282 treatment Methods 0.000 claims description 46
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical class OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 40
- 230000035935 pregnancy Effects 0.000 claims description 40
- 238000012360 testing method Methods 0.000 claims description 35
- 239000000203 mixture Substances 0.000 claims description 34
- 238000001262 western blot Methods 0.000 claims description 34
- 229920002971 Heparan sulfate Polymers 0.000 claims description 26
- 239000012530 fluid Substances 0.000 claims description 23
- 238000003556 assay Methods 0.000 claims description 17
- 238000003018 immunoassay Methods 0.000 claims description 15
- 238000011532 immunohistochemical staining Methods 0.000 claims description 15
- 239000003055 low molecular weight heparin Substances 0.000 claims description 14
- 229940127215 low-molecular weight heparin Drugs 0.000 claims description 14
- 229920000045 Dermatan sulfate Polymers 0.000 claims description 13
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 claims description 13
- 229940051593 dermatan sulfate Drugs 0.000 claims description 13
- 210000002536 stromal cell Anatomy 0.000 claims description 12
- 239000013068 control sample Substances 0.000 claims description 9
- 210000004696 endometrium Anatomy 0.000 claims description 9
- 201000005608 severe pre-eclampsia Diseases 0.000 description 77
- 102000007469 Actins Human genes 0.000 description 60
- 108010085238 Actins Proteins 0.000 description 60
- 108020004459 Small interfering RNA Proteins 0.000 description 59
- 210000004027 cell Anatomy 0.000 description 44
- 239000003636 conditioned culture medium Substances 0.000 description 43
- 230000016117 decidualization Effects 0.000 description 37
- 230000000694 effects Effects 0.000 description 37
- 238000002474 experimental method Methods 0.000 description 35
- 108010088842 Fibrinolysin Proteins 0.000 description 30
- 229940012957 plasmin Drugs 0.000 description 30
- 229960002897 heparin Drugs 0.000 description 27
- 229920000669 heparin Polymers 0.000 description 27
- 108090000623 proteins and genes Proteins 0.000 description 26
- 102000004169 proteins and genes Human genes 0.000 description 26
- 210000002993 trophoblast Anatomy 0.000 description 26
- 102000013566 Plasminogen Human genes 0.000 description 23
- 108010051456 Plasminogen Proteins 0.000 description 23
- 238000000338 in vitro Methods 0.000 description 23
- 230000005764 inhibitory process Effects 0.000 description 21
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 20
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 19
- 230000003834 intracellular effect Effects 0.000 description 19
- 101000627872 Homo sapiens 72 kDa type IV collagenase Proteins 0.000 description 18
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 description 18
- 102000004375 Insulin-like growth factor-binding protein 1 Human genes 0.000 description 16
- 108090000957 Insulin-like growth factor-binding protein 1 Proteins 0.000 description 16
- 238000004458 analytical method Methods 0.000 description 16
- 241000699666 Mus <mouse, genus> Species 0.000 description 15
- 238000010217 densitometric analysis Methods 0.000 description 15
- 230000003480 fibrinolytic effect Effects 0.000 description 15
- 230000028327 secretion Effects 0.000 description 14
- 206010052428 Wound Diseases 0.000 description 12
- 208000027418 Wounds and injury Diseases 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 11
- 102000008186 Collagen Human genes 0.000 description 10
- 108010035532 Collagen Proteins 0.000 description 10
- 229920001436 collagen Polymers 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 10
- 238000010186 staining Methods 0.000 description 10
- 238000001574 biopsy Methods 0.000 description 9
- 210000002459 blastocyst Anatomy 0.000 description 9
- 238000009792 diffusion process Methods 0.000 description 9
- 239000003527 fibrinolytic agent Substances 0.000 description 9
- 230000008595 infiltration Effects 0.000 description 9
- 238000001764 infiltration Methods 0.000 description 9
- 230000009545 invasion Effects 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 230000009467 reduction Effects 0.000 description 9
- 230000036772 blood pressure Effects 0.000 description 8
- 239000000284 extract Substances 0.000 description 8
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 8
- 230000007812 deficiency Effects 0.000 description 7
- 230000002950 deficient Effects 0.000 description 7
- 230000020764 fibrinolysis Effects 0.000 description 7
- 230000008774 maternal effect Effects 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 102000009123 Fibrin Human genes 0.000 description 6
- 108010073385 Fibrin Proteins 0.000 description 6
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 6
- 102000003946 Prolactin Human genes 0.000 description 6
- 108010057464 Prolactin Proteins 0.000 description 6
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 6
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 6
- 229950003499 fibrin Drugs 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 230000004899 motility Effects 0.000 description 6
- 230000027758 ovulation cycle Effects 0.000 description 6
- 229940097325 prolactin Drugs 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 229960000187 tissue plasminogen activator Drugs 0.000 description 6
- 102000000905 Cadherin Human genes 0.000 description 5
- 108050007957 Cadherin Proteins 0.000 description 5
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 5
- 206010020772 Hypertension Diseases 0.000 description 5
- 102100035071 Vimentin Human genes 0.000 description 5
- 108010065472 Vimentin Proteins 0.000 description 5
- 210000004292 cytoskeleton Anatomy 0.000 description 5
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 5
- 238000005462 in vivo assay Methods 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 238000012340 reverse transcriptase PCR Methods 0.000 description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- 210000005048 vimentin Anatomy 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 208000002296 eclampsia Diseases 0.000 description 4
- 210000002257 embryonic structure Anatomy 0.000 description 4
- 238000002825 functional assay Methods 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 150000007523 nucleic acids Chemical group 0.000 description 4
- 230000003076 paracrine Effects 0.000 description 4
- 108700038288 rhodamine-phalloidin Proteins 0.000 description 4
- 230000007480 spreading Effects 0.000 description 4
- 238000003892 spreading Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 201000005624 HELLP Syndrome Diseases 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000000090 biomarker Substances 0.000 description 3
- 230000004709 cell invasion Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 108091008147 housekeeping proteins Proteins 0.000 description 3
- 238000010191 image analysis Methods 0.000 description 3
- 238000013388 immunohistochemistry analysis Methods 0.000 description 3
- 239000000411 inducer Substances 0.000 description 3
- 210000001161 mammalian embryo Anatomy 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 210000003632 microfilament Anatomy 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 201000001474 proteinuria Diseases 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 230000008707 rearrangement Effects 0.000 description 3
- 238000007634 remodeling Methods 0.000 description 3
- 238000010877 transwell invasion assay Methods 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 2
- 239000012103 Alexa Fluor 488 Substances 0.000 description 2
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 2
- 102000005741 Metalloproteases Human genes 0.000 description 2
- 108010006035 Metalloproteases Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 2
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000003501 co-culture Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 210000000172 cytosol Anatomy 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 230000002074 deregulated effect Effects 0.000 description 2
- 230000003831 deregulation Effects 0.000 description 2
- 230000035487 diastolic blood pressure Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001378 electrochemiluminescence detection Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 239000000834 fixative Substances 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 238000009650 gentamicin protection assay Methods 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 102000036213 phospholipid binding proteins Human genes 0.000 description 2
- 108091011000 phospholipid binding proteins Proteins 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 230000000019 pro-fibrinolytic effect Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- MYIOYATURDILJN-UHFFFAOYSA-N rhodamine 110 Chemical compound [Cl-].C=12C=CC(N)=CC2=[O+]C2=CC(N)=CC=C2C=1C1=CC=CC=C1C(O)=O MYIOYATURDILJN-UHFFFAOYSA-N 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 241000948470 Amanita phalloides Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 238000011719 B6C3F1 mouse Methods 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000001951 Fetal Death Diseases 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 206010055690 Foetal death Diseases 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000924474 Homo sapiens Annexin A2 Proteins 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000000091 Maternal Death Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 101001037768 Plasmodium berghei 58 kDa phosphoprotein Proteins 0.000 description 1
- 208000005107 Premature Birth Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000001218 confocal laser scanning microscopy Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 210000003785 decidua Anatomy 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000032692 embryo implantation Effects 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 230000004578 fetal growth Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 208000000065 fibrinolytic defect Diseases 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 102000043255 human ANXA2 Human genes 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000007850 in situ PCR Methods 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000000464 low-speed centrifugation Methods 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 230000029849 luteinization Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 229960002985 medroxyprogesterone acetate Drugs 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000006740 morphological transformation Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008775 paternal effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 238000002135 phase contrast microscopy Methods 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 230000003331 prothrombotic effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- DMRMZQATXPQOTP-GWTDSMLYSA-M sodium;(4ar,6r,7r,7as)-6-(6-amino-8-bromopurin-9-yl)-2-oxido-2-oxo-4a,6,7,7a-tetrahydro-4h-furo[3,2-d][1,3,2]dioxaphosphinin-7-ol Chemical compound [Na+].C([C@H]1O2)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1Br DMRMZQATXPQOTP-GWTDSMLYSA-M 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 210000000685 uterine artery Anatomy 0.000 description 1
- 238000010865 video microscopy Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/36—Gynecology or obstetrics
- G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Reproductive Health (AREA)
- Pregnancy & Childbirth (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461968728P | 2014-03-21 | 2014-03-21 | |
| US61/968,728 | 2014-03-21 | ||
| US201461969520P | 2014-03-24 | 2014-03-24 | |
| US61/969,520 | 2014-03-24 | ||
| PCT/IB2015/001404 WO2015166353A2 (en) | 2014-03-21 | 2015-03-19 | Early detection of preeclampsia |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017513021A JP2017513021A (ja) | 2017-05-25 |
| JP2017513021A5 JP2017513021A5 (https=) | 2018-04-26 |
| JP6684263B2 true JP6684263B2 (ja) | 2020-04-22 |
Family
ID=54147245
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017500456A Expired - Fee Related JP6684263B2 (ja) | 2014-03-21 | 2015-03-19 | 子癇前症の早期検出 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20170097358A1 (https=) |
| EP (1) | EP3120152A2 (https=) |
| JP (1) | JP6684263B2 (https=) |
| CN (2) | CN106662589B (https=) |
| BR (1) | BR112016021630A2 (https=) |
| CA (1) | CA2943284A1 (https=) |
| MX (1) | MX384485B (https=) |
| WO (1) | WO2015166353A2 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010010201A1 (es) | 2008-07-22 | 2010-01-28 | Equipo Ivi Investigacion Sl | Perfil de expresion genetica como marcador de la receptividad endometrial |
| CN107073040A (zh) | 2014-06-17 | 2017-08-18 | 艾基诺米公司 | 子宫内膜病理状况中的干细胞治疗 |
| CA3074808A1 (en) * | 2017-09-05 | 2019-03-14 | Igenomix S.L. | Methods and devices for detecting biomarkers associated with preeclampsia |
| EP3781144A4 (en) * | 2018-03-06 | 2022-01-12 | The Feinstein Institutes for Medical Research | METHODS TO DETECT AND TREAT ENDOMETRIOSIS |
| CN114990038B (zh) * | 2022-05-24 | 2023-06-27 | 郑州大学 | 一种细菌外膜囊泡及其在制备先兆子痫治疗药物中的应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5712103A (en) * | 1995-02-13 | 1998-01-27 | Regents Of The University Of California | Diagnostic assay for the prediction of preeclampsia |
| IL127896A0 (en) * | 1998-12-31 | 1999-10-28 | Gail Laster | A novel treatment for preeclampsia and related diseases |
| WO2007030889A1 (en) * | 2005-09-15 | 2007-03-22 | Victor Voroteliak | Method of diagnosing pre-eclampsia |
| WO2008134881A1 (en) * | 2007-05-05 | 2008-11-13 | The University Of Western Ontario | Methods for the detection of preeclampsia |
| EP2019318A1 (en) * | 2007-07-27 | 2009-01-28 | Erasmus University Medical Center Rotterdam | Protein markers for cardiovascular events |
| CN101290321A (zh) * | 2008-04-11 | 2008-10-22 | 中国医学科学院肿瘤研究所 | 膜联蛋白a2的血清检测方法、检测试剂盒及其应用 |
| WO2009143633A1 (en) | 2008-05-30 | 2009-12-03 | Institut De Recherches Cliniques De Montreal | Pcsk9 inhibitors and methods of use thereof |
| CN110208540B (zh) * | 2008-10-31 | 2024-02-09 | 耶鲁大学 | 子痫前期检测和治疗的方法和组合物 |
| US20120107825A1 (en) * | 2010-11-01 | 2012-05-03 | Winger Edward E | Methods and compositions for assessing patients with reproductive failure using immune cell-derived microrna |
| WO2012115885A1 (en) * | 2011-02-22 | 2012-08-30 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Circulating biomarkers |
| US9423402B2 (en) * | 2011-11-30 | 2016-08-23 | Singapore Health Services Pte. Ltd. | GM1 ganglioside to annexin V microparticle polypeptide ratio for biological monitoring |
| WO2014001244A1 (en) * | 2012-06-27 | 2014-01-03 | Roche Diagnostics Gmbh | MEANS AND METHODS APPLYING sFlt-1/PlGF OR ENDOGLIN/PlGF RATIO TO RULE-OUT ONSET OF PREECLAMPSIA WITHIN A CERTAIN TIME PERIOD |
| CN103436552A (zh) * | 2013-09-10 | 2013-12-11 | 浙江大学 | 一种人源annexin A2的生产方法及其应用 |
-
2015
- 2015-03-19 BR BR112016021630-0A patent/BR112016021630A2/pt not_active IP Right Cessation
- 2015-03-19 EP EP15766246.1A patent/EP3120152A2/en not_active Withdrawn
- 2015-03-19 WO PCT/IB2015/001404 patent/WO2015166353A2/en not_active Ceased
- 2015-03-19 JP JP2017500456A patent/JP6684263B2/ja not_active Expired - Fee Related
- 2015-03-19 MX MX2016012278A patent/MX384485B/es unknown
- 2015-03-19 CN CN201580021153.7A patent/CN106662589B/zh not_active Expired - Fee Related
- 2015-03-19 CA CA2943284A patent/CA2943284A1/en not_active Abandoned
- 2015-03-19 US US15/127,901 patent/US20170097358A1/en not_active Abandoned
- 2015-03-19 CN CN201910597754.2A patent/CN110927385A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015166353A2 (en) | 2015-11-05 |
| WO2015166353A3 (en) | 2016-01-21 |
| CA2943284A1 (en) | 2015-11-05 |
| EP3120152A2 (en) | 2017-01-25 |
| CN106662589B (zh) | 2019-07-30 |
| BR112016021630A2 (pt) | 2020-02-27 |
| CN106662589A (zh) | 2017-05-10 |
| JP2017513021A (ja) | 2017-05-25 |
| CN110927385A (zh) | 2020-03-27 |
| US20170097358A1 (en) | 2017-04-06 |
| MX384485B (es) | 2025-03-14 |
| MX2016012278A (es) | 2017-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Garrido-Gomez et al. | Preeclampsia: a defect in decidualization is associated with deficiency of Annexin A2 | |
| Mamsen et al. | Characterization of follicles in girls and young women with Turner syndrome who underwent ovarian tissue cryopreservation | |
| Sasaki et al. | Hyperglycosylated human chorionic gonadotropin and the source of pregnancy failures | |
| JP6684263B2 (ja) | 子癇前症の早期検出 | |
| Lian et al. | Matrix metalloproteinase 1 in pre-eclampsia and fetal growth restriction: reduced gene expression in decidual tissue and protein expression in extravillous trophoblasts | |
| Siddiqui et al. | Decorin over-expression by decidual cells in preeclampsia: a potential blood biomarker | |
| Ajayi et al. | Elevated expression of serine protease HtrA1 in preeclampsia and its role in trophoblast cell migration and invasion | |
| Wang et al. | Overexpressed LAMC2 promotes trophoblast over‐invasion through the PI3K/Akt/MMP2/9 pathway in placenta accreta spectrum | |
| AU2023263563A1 (en) | Assay Method For Determining The Risk Of Pre-Eclampsia | |
| Wölfler et al. | A predictive model for endometriosis | |
| US20150038778A1 (en) | Itih5 as a diagnostic marker of uterine development and functional defects | |
| Sahlin et al. | Impaired leukocyte influx in cervix of postterm women not responding to prostaglandin priming | |
| RU2724381C1 (ru) | Способ оценки рецептивности эндометрия при эндометриоз-ассоциированном бесплодии | |
| Ibrahim et al. | Retracted: maternal serum amyloid a level as a novel marker of primary unexplained recurrent early pregnancy loss | |
| US20150168418A1 (en) | High-throughput early detection and point-of-care early detection of pregnant women susceptible to developing preeclampsia | |
| US20130130278A1 (en) | Detection of risk for pregnancy-related medical conditions | |
| US20230058124A1 (en) | Preeclampsia biomarkers and use thereof | |
| Chen et al. | Extracellular matrix induces trophoblast HtrA4 expression: Implications for the pathogenesis of placenta accreta spectrum | |
| US20180164323A1 (en) | Use of soluble cd146 as a biomarker to select in vitro-fertilized embryo for implantation in a mammal | |
| Wong et al. | Do uterine natural killer cell numbers in peri-implantation endometrium predict hypertensive disorder in pregnancy in women with a history of reproductive failure? | |
| HK40026831A (en) | Early detection of preeclampsia | |
| Fukasawa et al. | Factors related to deterioration of renal function after singleton delivery in pregnant women with chronic kidney disease | |
| AU2016330398B2 (en) | A method of treatment and prognosis | |
| Rood et al. | Tenascin-X in amniotic fluid and reproductive tissues of pregnancies complicated by infection and preterm prelabor rupture of membranes | |
| Rajashekhar et al. | Expression and secretion of the vascular cell adhesion molecule-1 in human placenta and its decrease in fetal growth restriction |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180316 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180316 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190205 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190426 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190603 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190805 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200127 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200226 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200327 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6684263 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |